A5052070182- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
- Clostridium difficile and Clostridium perfringens research
- Antifungal resistance and susceptibility
- Antimicrobial Resistance in Staphylococcus
- Infectious Diseases and Mycology
- Fungal Infections and Studies
- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Antibiotic Resistance in Bacteria
- Diet and metabolism studies
- Mycobacterium research and diagnosis
- Bacterial biofilms and quorum sensing
- Diabetes Management and Research
- Infections and bacterial resistance
Kern Medical Center
2016-2024
University of the Pacific
2016
Background In order to reduce Centers for Medicare and Medicaid Services (CMS)‐directed readmission penalties improve patient discharge care, a bedside medication delivery service was developed. Objective To evaluate the impact of pharmacist consultation (Meds‐to‐Beds; MtB) on 30‐day rates at an academic hospital. Methods The pharmacist‐led MtB program established in September 2016. Unplanned data other disease severity indicators were retrospectively collected from 2015 January 2017....
Hypersensitivity to triazoles is a rare occurrence and cross-reactivity between agents unknown. We present successful voriconazole challenge in patient allergic fluconazole itraconazole.A 41-year-old immunocompetent male with coccidioidomycosis developed fever, eosinophilia maculopapular rash from fluconazole. Switching itraconazole resulted worsening of the skin sloughing over 25% his body. He was given an oral-graded which he tolerated without incident.This first report lack voriconazole.
Stenotrophomonas maltophilia is an inherently multidrug resistant (MDR) opportunistic pathogen with many mechanisms of resistance. SENTRY studies reveal decreasing sensitivities S. to trimethoprim-sulfamethoxazole and fluoroquinolones. Ceftolozane-tazobactam (Zerbaxa, Merck & Co., Inc.) a novel intravenous combination agent third-generation cephalosporin β -lactamase inhibitor was demonstrated have in vitro activity against Gram-positive, Gram-negative, MDR organisms. Data for...
Abstract Introduction In 2019, California Governor Gavin Newsom introduced executive order N‐01‐19, which transitioned California's Medicaid (Medi‐Cal) health plan pharmacy benefits from multiple managed care plans to a single‐payer system. This transition occurred on January 1, 2022, and Medi‐Cal stopped enforcing formulary restrictions for beneficiaries. Objectives study compared glycemic control of hemoglobin A1c in pharmacist‐led diabetes clinic during an open versus restrictive...